Results 101 to 110 of about 1,058,979 (232)
Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer
MedComm, Volume 7, Issue 10, October 2026.Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta +2 more
wiley +1 more source
Oncolytic viruses (OV) selectively replicate and kill cancer cells and spread within the tumor, while not harming normal tissue. Besides this direct oncolytic activity, OVs are also very effective at inducing immune responses to themselves and the infected tumor cells.
openaire +3 more sources
The evolving role of immunotherapy in ovarian cancer
Cancer, Volume 132, Issue 18, 15 September 2026.Abstract Ovarian cancer remains a major cause of gynecologic cancer mortality; and, although immune checkpoint inhibitors have transformed treatment in other solid tumors, their activity in ovarian cancer has been limited by tumor heterogeneity, an immunosuppressive tumor microenvironment, and the lack of robust predictive biomarkers.
Ana Carolina Veneziani +2 more
wiley +1 more source
Frontiers in Oncology, 2014 Oncolytic viral therapies have recently found their way into clinical application for hepatocellular carcinoma (HCC), a disease with limited treatment options and poor prognosis. Adding to the many intrinsic challenges of in vivo oncolytic viral therapy,
Oliver eEbert, Jennifer eAltomonte
doaj +1 more source
Superantigens in Cancer Immunotherapy: Mechanisms, Engineering Strategies, and Therapeutic Potential
The FASEB Journal, Volume 40, Issue 17, 15 September 2026.Schematic overview of superantigen‐mediated antitumor immune responses and immune suppression within the tumor microenvironment. (1) Antigen‐presenting cells activate T cells through MHC‐II/TCR interactions resulting in the production of cytokines (2) The pro‐inflammatory cytokines released by activated immune cells stimulate downstream immune ...
Urooj Yousaf Virk +5 more
wiley +1 more source
Natural Killer Cells in Paediatric Soft Tissue Sarcomas: A Systematic Review
Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.ABSTRACT Paediatric soft tissue sarcomas (pSTS) are a rare and heterogeneous group of malignant tumours arising in tissues of mesenchymal origin. The role of natural killer (NK) cells in pSTS remains poorly understood, with evidence fragmented across small preclinical studies and early‐phase clinical trials.
Raya Dean +7 more
wiley +1 more source
Nanomaterial Strategies for Pulmonary Delivery of Immunotherapeutics in Lung Cancer Treatment
Advanced Healthcare Materials, Volume 15, Issue 34, 11 September 2026.Inhalable immunotherapeutic nanomedicines enable organ‐selective immune modulation by overcoming pulmonary delivery barriers and concentrating therapy within lung tumors. This Review defines how nanomaterial properties govern airway deposition, retention, cellular partitioning, and immune activation across vaccines, checkpoint blockade, STING agonists,
Han Zhang, Wei Tang
wiley +1 more source
Advanced Science, Volume 13, Issue 52, 18 September 2026.RT promotes VG161 replication in BC and its immunostimulatory transgenes expression, which is mediated by the upregulation of GADD34 and HVEM caused by RT. The combination therapy with VG161 and RT increases the abundances of tumor‐infiltrating lymphocytes and elicits potent systemic antitumor immunity, thereby effectively inhibiting local tumors and ...
Lijuan Lyu +13 more
wiley +1 more source
CCL3 and IL‐7 Synergistically Enhance CAR‐T Efficacy in Solid Tumors
Advanced Science, Volume 13, Issue 49, 3 September 2026.Synergistic delivery of CCL3 and IL‐7 by CAR‐T cells overcomes the immunosuppressive tumor microenvironment by enhancing cell infiltration, survival, and local immune reprogramming. This also establishes positive feedback that amplifies anti‐tumor activity and memory responses in both CAR‐T and endogenous T cells, presenting a robust therapeutic ...
Huanpeng Chen +12 more
wiley +1 more source
Advanced Science, Volume 13, Issue 51, 14 September 2026.Cancer vaccines face limitations in pancreatic cancer due to insufficient tumor antigens. This ionic liquid ILvax via local tumor delivery triggers robust cDC1‐dependent systemic anti‐tumor immunity. It boosts endogenous CD8+ T cells and optimizes adoptive TCR‐T function, providing a promising synergistic therapeutic strategy.
Junming Huang +11 more
wiley +1 more source